CN Patent

CN115626923B — Kras g12c抑制剂及其使用方法

Assigned to Amgen Inc · Expires 2024-08-02 · 2y expired

What this patent protects

本发明涉及KRASG12C抑制剂及其使用方法。本文提供KRASG12C抑制剂、其组合物及其使用方法。这些抑制剂可用于治疗多种病症，包括胰腺癌、结肠直肠癌及肺癌。

USPTO Abstract

本发明涉及KRASG12C抑制剂及其使用方法。本文提供KRASG12C抑制剂、其组合物及其使用方法。这些抑制剂可用于治疗多种病症，包括胰腺癌、结肠直肠癌及肺癌。

Drugs covered by this patent

Patent Metadata

Patent number
CN115626923B
Jurisdiction
CN
Classification
—
Expires
2024-08-02
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.